Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 2
2018 2
2019 1
2020 1
2021 4
2022 10
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.
Halpern AB, Rodríguez-Arbolí E, Othus M, Garcia KA, Percival MM, Cassaday RD, Oehler VG, Becker PS, Appelbaum JS, Abkowitz JL, Orozco JJ, Keel SB, Hendrie PC, Scott BL, Ghiuzeli MC, Estey EH, Walter RB. Halpern AB, et al. Among authors: rodriguez arboli e. Blood Adv. 2023 Sep 12;7(17):4950-4961. doi: 10.1182/bloodadvances.2023010392. Blood Adv. 2023. PMID: 37339483 Free PMC article. Clinical Trial.
Prognostic Value of Measurable Residual Disease in Patients with AML Undergoing HSCT: A Multicenter Study.
Caballero-Velázquez T, Pérez-López O, Yeguas Bermejo A, Rodríguez Arbolí E, Colado Varela E, Sempere Talens A, Vidriales MB, Solé-Rodríguez M, Quirós Caso C, Pérez López E, Reinoso Segura M, Prats-Martín C, Montesinos P, Pérez-Simón JA. Caballero-Velázquez T, et al. Among authors: rodriguez arboli e. Cancers (Basel). 2023 Mar 5;15(5):1609. doi: 10.3390/cancers15051609. Cancers (Basel). 2023. PMID: 36900400 Free PMC article.
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group.
Sargas C, Ayala R, Larráyoz MJ, Chillón MC, Rodriguez-Arboli E, Bilbao C, Prados de la Torre E, Martínez-Cuadrón D, Rodríguez-Veiga R, Boluda B, Gil C, Bernal T, Bergua J, Algarra L, Tormo M, Martínez-Sánchez P, Soria E, Serrano J, Alonso-Dominguez JM, García R, Amigo ML, Herrera-Puente P, Sayas MJ, Lavilla-Rubira E, Martínez-López J, Calasanz MJ, García-Sanz R, Pérez-Simón JA, Gómez Casares MT, Sánchez-García J, Barragán E, Montesinos P; PETHEMA cooperative study group. Sargas C, et al. Among authors: rodriguez arboli e. Blood Cancer J. 2023 May 12;13(1):77. doi: 10.1038/s41408-023-00835-5. Blood Cancer J. 2023. PMID: 37173322 Free PMC article.
Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission.
Walter RB, Sandmaier BM, Othus M, Orvain C, Rodríguez-Arbolí E, Oshima MU, Schoch G, Davis C, Joachim Deeg H, Storb R. Walter RB, et al. Among authors: rodriguez arboli e. Bone Marrow Transplant. 2023 Apr;58(4):377-385. doi: 10.1038/s41409-022-01909-x. Epub 2022 Dec 28. Bone Marrow Transplant. 2023. PMID: 36577856
Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials.
Rodríguez-Arbolí E, Lee CJ, Caballero-Velázquez T, Martínez C, García-Calderón C, Jiménez-León MR, Bermúdez-Rodríguez MA, López-Corral L, Triguero A, Onstad L, Horwitz ME, Sarantopoulos S, Lee SJ, Pérez-Simón JA. Rodríguez-Arbolí E, et al. Clin Cancer Res. 2023 Oct 13;29(20):4057-4067. doi: 10.1158/1078-0432.CCR-23-0666. Clin Cancer Res. 2023. PMID: 37698881
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
Martínez-Cuadrón D, Megías-Vericat JE, Serrano J, Martínez-Sánchez P, Rodríguez-Arbolí E, Gil C, Aguiar E, Bergua J, López-Lorenzo JL, Bernal T, Espadana A, Colorado M, Rodríguez-Medina C, López-Pavía M, Tormo M, Algarra L, Amigo ML, Sayas MJ, Labrador J, Rodríguez-Gutiérrez JI, Benavente C, Costilla-Barriga L, García-Boyero R, Lavilla-Rubira E, Vives S, Herrera P, García-Belmonte D, Herráez MM, Vasconcelos Esteves G, Gómez-Roncero MI, Cabello A, Bautista G, Balerdi A, Mariz J, Boluda B, Sanz MÁ, Montesinos P. Martínez-Cuadrón D, et al. Among authors: rodriguez arboli e. Blood Adv. 2022 Feb 22;6(4):1278-1295. doi: 10.1182/bloodadvances.2021005335. Blood Adv. 2022. PMID: 34794172 Free PMC article. Clinical Trial.
SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.
Falantes JF, Márquez-Malaver FJ, Carrillo E, Culebras MG, Morales R, Prats C, Vargas MT, Caballero T, Rodríguez-Arbolí E, Espigado I, Pérez-Simón JA. Falantes JF, et al. Among authors: rodriguez arboli e. Clin Lymphoma Myeloma Leuk. 2022 Dec;22(12):e1059-e1066. doi: 10.1016/j.clml.2022.08.012. Epub 2022 Aug 27. Clin Lymphoma Myeloma Leuk. 2022. PMID: 36117041
Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed/refractory acute myeloid leukemia: an EBMT analysis.
Rodríguez-Arbolí E, Labopin M, Eder M, Brecht A, Blau IW, Huynh A, Forcade E, Tischer J, Bethge W, Bondarenko S, Verbeek M, Bulabois CE, Einsele H, Stölzel F, Savani B, Spyridonidis A, Bazarbachi A, Giebel S, Brissot E, Schmid C, Nagler A, Mohty M. Rodríguez-Arbolí E, et al. Bone Marrow Transplant. 2022 Jun;57(6):934-941. doi: 10.1038/s41409-022-01611-y. Epub 2022 Apr 7. Bone Marrow Transplant. 2022. PMID: 35393528
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry.
Labrador J, Martínez-Cuadrón D, de la Fuente A, Rodríguez-Veiga R, Serrano J, Tormo M, Rodriguez-Arboli E, Ramos F, Bernal T, López-Pavía M, Trigo F, Martínez-Sánchez MP, Rodríguez-Gutiérrez JI, Rodríguez-Medina C, Gil C, Belmonte DG, Vives S, Foncillas MÁ, Pérez-Encinas M, Novo A, Recio I, Rodríguez-Macías G, Bergua JM, Noriega V, Lavilla E, Roldán-Pérez A, Sanz MA, Montesinos P, On Behalf Of Pethema Group. Labrador J, et al. Among authors: rodriguez arboli e. Cancers (Basel). 2022 May 9;14(9):2342. doi: 10.3390/cancers14092342. Cancers (Basel). 2022. PMID: 35565471 Free PMC article.
27 results